Life Science Investing First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis , Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI 02 September
Life Science Investing Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update 12 August
life science investing Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference 20 April 2023
